Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.018x

Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL174.79 Million ≈ $3.91 Million USD) by net assets (TL9.76 Billion ≈ $218.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Cash Flow Conversion Efficiency Trend (2018–2024)

This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GENIL total liabilities for a breakdown of total debt and financial obligations.

Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
N/A
Genus Power Infrastructures Limited
NSE:GENUSPOWER
-0.083x
Green Plains Renewable Energy Inc
NASDAQ:GPRE
0.087x
Middlesex Water Company
NASDAQ:MSEX
0.025x
Shanxi Guoxin Energy Co Ltd A
SHG:600617
0.151x
SEP Analytical (Shanghai) Co. Ltd.
SHE:301228
N/A
Sagicor Financial Company
TO:SFC
0.295x
Zee Entertainment Enterprises Limited
NSE:ZEEL
-0.002x

Annual Cash Flow Conversion Efficiency for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)

The table below shows the annual cash flow conversion efficiency of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Gen Ilac ve Saglik Urunleri Sanayi ve Ti.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 TL7.31 Billion
≈ $163.67 Million
TL1.99 Billion
≈ $44.65 Million
0.273x +647.34%
2023-12-31 TL7.01 Billion
≈ $157.11 Million
TL256.05 Million
≈ $5.73 Million
0.037x +533.85%
2022-12-31 TL2.80 Billion
≈ $62.81 Million
TL16.15 Million
≈ $361.73K
0.006x -95.34%
2021-12-31 TL1.28 Billion
≈ $28.76 Million
TL158.83 Million
≈ $3.56 Million
0.124x -30.18%
2020-12-31 TL557.36 Million
≈ $12.48 Million
TL98.74 Million
≈ $2.21 Million
0.177x -73.86%
2019-12-31 TL245.48 Million
≈ $5.50 Million
TL166.39 Million
≈ $3.73 Million
0.678x +270244.50%
2018-12-31 TL112.59 Million
≈ $2.52 Million
TL28.23K
≈ $632.21
0.000x --

About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS

IS:GENIL Turkey Drug Manufacturers - Specialty & Generic
Market Cap
$933.30 Million
TL41.67 Billion TRY
Market Cap Rank
#9400 Global
#77 in Turkey
Share Price
TL9.26
Change (1 day)
-2.63%
52-Week Range
TL7.17 - TL216.90
All Time High
TL216.90
About

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more